Where is there still room in longevity?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
There is still substantial room in longevity, but the best openings are no longer generic "anti-aging" companies. The strongest opportunities sit in muscle preservation, immune rejuvenation, clinically useful biomarkers, focused preventive care, dog longevity and specialized infrastructure around organ replacement or cellular reprogramming.
Longevity looks more crowded from the outside than it does underneath. Funding is heavily concentrated in a few names and themes, so large category totals overstate how many well-capitalized competitors actually exist across the rest of the market.
The competitive bar has also moved. Mouse data and broad claims about reversing aging are no longer enough when companies such as Life Biosciences and Retro are already dosing humans and NewLimit is preparing to do the same.
The practical regulatory route is becoming clearer: do not ask regulators to approve "aging." Start with a disease or loss of function that becomes more common with age, prove benefit there, then expand outward.
Muscle stands out because the market has both an old problem and a new one. Sarcopenia still lacks an approved drug, while widespread GLP-1 use has created fresh demand for treatments that preserve useful lean tissue during major weight loss.
Immune rejuvenation is earlier, harder and less crowded. The biology is compelling, but the lack of an accepted clinical measure of "immune age" means the most attractive companies will probably enter through severe, measurable immune-recovery problems first.
Aging biomarkers remain one of the most important infrastructure gaps. Many clocks can detect change, but the field still cannot reliably say what a one-year shift in "biological age" means for future disease, function or survival.
Consumer prevention is not closed, but horizontal testing is becoming a bad place to start. Neko Health, Function Health and Prenuvo already have scale, so a new company is better off owning a narrower clinical decision such as menopause, cancer survivorship, inherited cardiovascular risk or post-GLP-1 care.
Dog longevity is unusually interesting because lifespan itself can be tested on a commercially useful timeline. Loyal is showing that a regulated longevity product can move toward market in animals before the equivalent path is realistic in healthy humans.
The common thread is measurable benefit. The best longevity startups now have to show that people see better, move better, recover immunity, preserve function or make better medical decisions - not just that a molecular marker looks younger.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
What does "room" in longevity actually mean today?
Today, the best room in longevity sits where age-related decline can be measured in real patients, treated through a credible medical path and improved without waiting ten years for an answer.
That narrows the market quickly. A longevity company can discover interesting aging biology and still make a terrible startup if proving that biology requires a decade-long lifespan trial, regulators have no usable endpoint, or customers already have a cheaper way to get roughly the same result.
We therefore see two very different types of opportunity. The first is medical: muscle loss, immune decline, tissue degeneration and other problems that become much more common with age but can already be treated as recognizable diseases. The second is infrastructure: biomarkers, trial design, patient cohorts and clinical tools that make it easier to tell whether an intervention is actually changing aging.
Consumer preventive health belongs in the picture too, but the bar is much higher these days. Neko Health, Function Health, Prenuvo and several clinic networks have already proved that wealthy consumers will pay to measure more of their health.
So when we ask where there is still room in longevity, we are looking for places where the problem remains large, the current answer is poor, and a startup can learn something important before running out of money.
If you want more recent data on this point, please see our latest longevity market report.
Is the longevity startup market already too crowded?
The longevity startup market still has plenty of room, although funding makes it look much more crowded than it really is.
We reviewed 37 disclosed longevity financings from Q2 2025 through Q2 2026. Together, those companies raised about $1.64 billion.
The capital distribution tells a different story from the headline total. The three largest financings represented 52.5% of all the money raised during those five quarters. In Q2 2026, NewLimit alone accounted for 68% of the quarter's $636 million total. Remove that $435 million round and the other eight companies raised about $201 million combined.
The category split is just as revealing. Therapeutics took roughly $1.02 billion, or 62% of all disclosed funding. Preventive-health platforms received about $374 million. Consumer longevity brands took around $138 million. Within each group, a handful of unusually large rounds pulled up the totals.
Since then, the concentration has become even more obvious. Neko Health recently raised another $700 million at a reported valuation close to $7 billion.
A few positions are clearly crowded. General preventive testing now has heavily funded companies. Epigenetic reprogramming does too. The broader map remains surprisingly sparse once we start asking who has human data, who has an approved product and who has built something difficult to copy.
| Longevity category | Deals reviewed | Capital raised | What the number hides |
|---|---|---|---|
| Therapeutics | 16 | ~$1.02B | NewLimit alone raised $610M across three rounds |
| Preventive-health platforms | 5 | ~$374M | Function Health contributed $298M |
| Consumer longevity | 5 | ~$138M | Capital remains concentrated in a few brands |
| Entire market | 37 | ~$1.64B | Top three rounds captured 52.5% of all funding |
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Are longevity drugs finally reaching real human trials?
Yes. Longevity biotech is finally producing a small but meaningful group of human trials, which changes what a new startup has to prove.
Retro Biosciences currently has RTR242 in a Phase 1 study in Australia. The drug targets lysosomal function and autophagy, processes that deteriorate with age and are implicated in neurodegeneration. After its earlier dose cohorts produced no major safety problem but left the company wanting a stronger pharmacological effect, Retro recently increased planned enrollment from 76 to 108 people and moved into higher doses.
Retro went from selecting an indication to first-in-human dosing in roughly 15 months, according to the company. We still have no evidence that RTR242 will improve Alzheimer's disease or extend healthy life, but aging biology is now being tested in people rather than inferred entirely from mice.
Life Biosciences has crossed another important line. Its ER-100 program uses controlled expression of OCT4, SOX2 and KLF4 to partially reprogram cells in the optic nerve. The FDA cleared the program for human testing, the first patient has been dosed, and the Phase 1 study plans to enroll 18 people with glaucoma or non-arteritic anterior ischemic optic neuropathy.
NewLimit is moving in the same direction. After raising $435 million, the company says its first reprogramming medicine should enter human trials next year. Its initial program is being developed around liver disease rather than asking regulators to approve a treatment for aging itself.
Human evidence remains extremely thin, but that now gives clinically fast startups a real way to stand out. Another preclinical platform with strong mouse data will face a much higher bar than it did five years ago.
Can a longevity startup get a drug approved if aging is not an FDA indication?
A longevity startup can reach the FDA today, but the practical route usually runs through a specific disease or loss of function rather than "aging" itself.
Life Biosciences offers a clean example. ER-100 comes from a cellular-rejuvenation platform, yet the human study is enrolling patients with glaucoma and non-arteritic anterior ischemic optic neuropathy. Regulators can evaluate safety, vision and optic-nerve outcomes without first deciding how to regulate biological age.
HexemBio is taking a similar route with blood stem-cell rejuvenation. The company's broader thesis is that aging hematopoietic stem cells contribute to immune decline and systemic aging. Its first clinical target, however, is improving bone-marrow transplantation in blood-cancer patients. HexemBio received FDA Orphan Drug Designation for that use and has already completed a pre-IND meeting.
Juvena Therapeutics is doing something comparable in muscle. Its regenerative-biology platform has obvious healthy-aging implications, while the first JUV-161 trials target myotonic dystrophy, a recognized muscle disease.
The strongest route is fairly clear: find an age-linked disease where the mechanism matters, prove the biology there and expand later. Better vision, stronger muscle or improved immune reconstitution are also much easier to evaluate than a vague claim that patients became "younger."
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Can a new longevity startup still compete with Neko Health, Function Health and full-body scan companies?
A new longevity startup can still compete in preventive health, but another broad testing membership or standalone full-body scan now looks like a weak starting point.
Neko Health has become the clearest warning. The company has delivered more than 100,000 scans, attracted more than 350,000 people to its registration and waitlist funnel, and recently raised $700 million for expansion. Its first U.S. clinic is scheduled to open in New York, with the company bringing proprietary imaging hardware, blood testing and clinician review into the same visit.
Function Health built a different version of the same ambition. Its membership centers on recurring laboratory testing and the company has expanded into imaging and AI-based interpretation. Function raised $298 million at a $2.5 billion valuation, bringing disclosed capital raised to about $350 million.
Prenuvo has already completed more than 150,000 scans across 27 clinics and currently charges $2,499 for its standalone whole-body MRI in the United States. The company raised $120 million and has steadily added blood testing, neurological measurements and body-composition analysis around the original scan.
Consumer demand is clearly there. The harder question is whether broad screening improves outcomes enough to justify the cost and follow-up burden. The American College of Radiology still says there is insufficient evidence to recommend total-body MRI screening for asymptomatic people without relevant risk factors, symptoms or family history.
Prenuvo's own data illustrates the problem from another angle. Among its first 100,000 scans, the company said 49% of patients had something worth monitoring. A result appearing on a scan and a result that improves someone's eventual health outcome are different thresholds.
The openings we see are narrower: menopause, cancer survivorship, rapid weight loss, inherited cardiovascular risk, patient selection for imaging, incidental-finding management and deciding which abnormalities actually deserve action.
A new company has a much better chance owning one of those decisions than trying to out-test Function, out-scan Prenuvo or outspend Neko.
If you want more recent data on this point, please see our latest longevity market report.
Is there still room for a better biological-age test?
There is substantial room for better aging biomarkers right now, while another consumer score claiming that someone is "42 biologically" looks increasingly easy to copy.
One of the freshest pieces of evidence is a large Nature Medicine analysis that harmonized 51 human intervention studies. Researchers recalculated 16 well-known epigenetic clocks plus 94 other DNA-methylation biomarkers across 3,128 samples instead of accepting whatever aging clock each original study had chosen.
The results were messy enough to explain why this opportunity remains open. Nineteen interventions significantly reduced epigenetic age across the clocks they examined, but only 13 remained significant after correction for multiple testing. Twenty-six interventions produced no significant reduction. Some clocks also responded much more consistently than others.
Second-generation measures linked to mortality or pace of aging, including DunedinPACE and PCGrimAge, generally performed better than simple chronological-age predictors. Pharmacological interventions produced larger average changes than supplements, while lifestyle interventions showed useful consistency across biomarkers.
Researchers still could not establish the thing drug developers ultimately need: a clinically meaningful amount of change. If a treatment moves an epigenetic clock by one year, we cannot simply conclude that it gave the patient one extra year of healthy life.
A separate Nature Medicine review published recently found the same basic problem in immune aging: many age-related immune changes can be measured, but there is no single accepted biomarker that tells a clinical trial, with enough confidence, that an immune intervention has rejuvenated a person.
The serious opportunity is connecting short-term biomarker movement to later disease, function or survival well enough that drug developers can use the measurement in real trials.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Is epigenetic reprogramming already too crowded for a new startup?
A broad epigenetic-reprogramming startup would enter a difficult race today, but important parts of reprogramming remain wide open.
NewLimit has become the obvious benchmark. The company raised $435 million in its latest round at a valuation of about $3.1 billion and intends to take its first aging-reprogramming medicine into humans next year. It has concentrated initially on old liver cells and says a prototype treatment can restore more youthful patterns of cellular function.
Life Biosciences is already one step further clinically. Its $80 million financing is supporting ER-100, the 18-person Phase 1 optic-neuropathy study described above. That program matters because partial reprogramming has finally moved from a theoretical safety discussion into an actual human safety test.
The unanswered questions remain enormous. How much reprogramming produces useful restoration before cells lose identity? How do we deliver transcription factors to exactly the tissue we want? How often can treatment be given? Does a younger molecular profile restore organ function? Can the effect last? What happens years later?
Those questions leave room for specialized companies working on delivery, control switches, tissue-specific vectors, safer factor combinations or indications where a small amount of restored function can be measured quickly.
We would be much less excited by a new company whose pitch stops at "we discovered another way to make cells younger." NewLimit and Life Biosciences have made that bar obsolete.
| Company | Reprogramming position today | Clinical status | Main thing still to prove |
|---|---|---|---|
| Life Biosciences | Partial epigenetic restoration using OSK | Phase 1 dosing underway | Human safety and restored visual function |
| NewLimit | Reprogramming medicines initially focused on liver cells | First trial planned | Translation into meaningful human benefit |
| Retro Biosciences | Tissue reprogramming is one part of a broader longevity pipeline | Reprogramming remains preclinical | Delivery and efficacy in a defined disease |
Are senolytics still worth building after the first disappointments?
Senolytics are still worth investigating, but the broad "clear senescent cells and aging improves" startup pitch has lost a lot of credibility.
Unity Biotechnology is the obvious warning. The company became one of the best-known commercial bets on cellular senescence, struggled to turn that biology into convincing clinical efficacy and eventually moved toward dissolution after setbacks in its ophthalmology program.
Academic human trials have produced a more interesting picture.
In a randomized Phase 2 study of 60 postmenopausal women, intermittent dasatinib plus quercetin failed to improve the primary bone-resorption endpoint versus control. An exploratory analysis then found something potentially important: women with the highest measured senescent-cell burden showed larger biological responses, including a 2.7% increase in radius bone-mineral density after 20 weeks.
A separate pilot involving 12 older adults at risk for Alzheimer's disease found that dasatinib plus quercetin could be administered without treatment-related serious adverse events. Cognitive and inflammatory results were mixed, and such a small uncontrolled study cannot establish efficacy.
Those studies make patient selection look more important than the first generation of senolytic companies assumed. A stronger startup could identify which patients actually have high senescent-cell burden, target one tissue more selectively or suppress harmful senescence signaling without indiscriminately killing senescent cells.
We would still rank senolytics below muscle or immune rejuvenation today because the human efficacy case remains much weaker.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Is immune rejuvenation still underbuilt in longevity?
Immune rejuvenation is one of the clearest underbuilt areas in longevity today, especially compared with the money already chasing cellular reprogramming.
The biological case is broad. The thymus shrinks with age. Production of naive T cells falls. Hematopoietic stem cells change their output. Chronic inflammation rises. Vaccine responses weaken. Cancer surveillance and recovery from infection also deteriorate.
Commercial development is only starting to catch up.
TECregen raised CHF 10 million, roughly $12.6 million at the time, in a seed round led by Boehringer Ingelheim Venture Fund. The company is developing biologics intended to regenerate thymic epithelial cells and restore T-cell production. Its initial medical opportunities include immune recovery after transplantation or cytotoxic therapy, where there is already a clear patient need.
HexemBio recently emerged with a $10.4 million seed round led by Draper Associates. Its approach focuses on rejuvenating a patient's own hematopoietic stem cells outside the body by exposing them to a synthetic version of the developmental environment in which young blood stem cells originally form. The company plans to enter through bone-marrow transplantation rather than start with healthy aging.
Together, TECregen and HexemBio have raised about $23 million. NewLimit raised $435 million in one round. Stage differences explain part of that gap, but the comparison still shows how early immune restoration is as a venture category.
There is a real problem to solve before we get too excited. The recent Nature Medicine review of immune-aging biomarkers found no universally accepted clinical measure of "immune age." A company can potentially restore T-cell diversity, reduce inflammatory markers or improve vaccine responses without knowing which change regulators will eventually accept as evidence of meaningful rejuvenation.
That uncertainty makes immune rejuvenation harder, but also keeps the field open. We would look particularly closely at startups that begin with a severe, measurable immune-recovery problem and build toward broader age-related immune decline from there.
Is muscle the clearest near-term longevity drug opportunity now?
Muscle is probably the cleanest near-term longevity drug opportunity we see today because aging creates a huge clinical need, no FDA-approved drug exists for sarcopenia, and the GLP-1 boom has added another reason to preserve muscle.
The FDA continues to describe sarcopenia as progressive age-related loss of muscle function and mass, with current treatment centered on physical activity and nutrition. Despite decades of work on myostatin, anabolic pathways and muscle regeneration, no drug has yet become the standard answer.
Meanwhile, obesity medicine has created a new opening. A recent meta-analysis of seven randomized GLP-1 trials covering 821 patients found that obesity-dose GLP-1 therapy reduced absolute lean mass by an average of 1.74 kilograms. The percentage of body weight represented by lean tissue actually improved because fat loss was larger, so the result should not be interpreted as "GLP-1 drugs destroy muscle." It does show that meaningful absolute lean-tissue loss can accompany major weight reduction.
Drug developers are already moving.
iBio recently dosed the first participant in its Phase 1 trial of IBIO-600, a long-acting anti-myostatin antibody designed to preserve muscle during weight loss. The randomized study plans to enroll about 32 adults with overweight or obesity and will track body composition and physical function alongside safety.
Juvena Therapeutics is approaching muscle from regenerative biology. The company raised $33.5 million this year while JUV-161 was already in Phase 1 studies, and Eli Lilly has entered a separate research collaboration with Juvena around muscle health.
This creates several ways into the market: frailty, sarcopenia, muscle loss during obesity treatment, recovery after hospitalization and specific muscle diseases. The difficult part will be proving useful function. A drug that makes a DEXA scan look better but does not improve strength, mobility, falls or independence has limited longevity value.
For now, muscle combines unusually good startup characteristics: a huge aging-linked problem, measurable endpoints, active pharmaceutical interest and no established pharmacological winner.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Is women's midlife health a better longevity wedge than another anti-aging clinic?
Women's midlife health is a stronger longevity entry point than a generic anti-aging clinic because people already have concrete problems to solve and insurers already understand much of the care.
Midi Health shows how large that wedge can become. The company started around perimenopause and menopause, then expanded into areas including cardiovascular care, endocrinology, obesity, sleep, cancer survivorship and longevity.
Midi now says more than 25,000 patients use its care each week and its insurance coverage reaches more than 45 million women. The company recently raised $100 million at a valuation above $1 billion.
The expansion makes sense because menopause rarely arrives as an isolated longevity problem. Bone loss accelerates. Body composition changes. Cardiovascular risk becomes increasingly important. Sleep, metabolic health and muscle all interact. A company that already treats the immediate symptoms can build a longer relationship around those later risks.
Midi also reports encouraging operational outcomes, including a 28-percentage-point increase in breast-cancer screening adherence and an 11-point increase in colorectal-cancer screening adherence among the populations it analyzed. Those figures come from company data rather than independent randomized trials, so we would treat them accordingly, but they show the type of outcome a preventive-care company can actually measure.
There are other underserved transitions with similar potential: cancer survivorship, post-GLP-1 weight maintenance, premature menopause, high inherited cardiovascular risk and recovery after major illness.
A focused clinical wedge gives people a reason to show up today. Once trust, insurance coverage and longitudinal data exist, longevity becomes a natural expansion rather than the product's only selling point.
Can dog longevity become a serious business before human longevity does?
Dog longevity has a realistic chance of producing a regulated lifespan-extension product before human longevity does.
Loyal is now far beyond a small geroscience experiment. The company raised $100 million in its latest round, bringing total investment since founding above $250 million. Its STAY trial has enrolled 1,300 dogs across 70 veterinary clinics, making it one of the largest veterinary clinical trials ever conducted.
More importantly, the FDA's Center for Veterinary Medicine has already accepted two of the three major technical sections Loyal needs for expanded conditional approval of LOY-002: reasonable expectation of effectiveness and target-animal safety. The remaining major section concerns manufacturing.
That is unusually tangible progress for longevity. Most human companies are still trying to show that a biomarker changed or that a disease-specific therapy is safe. Loyal is attempting to commercialize a prescription drug with lifespan extension itself at the center of the claim.
Dogs also solve part of the experimental-timeline problem. They share households and many environmental exposures with humans while aging much faster. Researchers can therefore observe survival and healthspan within a period that would be impractical in initially healthy humans.
Translation remains uncertain. A drug that extends healthy canine lifespan does not automatically become a human longevity drug. Veterinary pricing, metabolism and disease patterns also differ.
Even with those limits, companion-animal longevity has something most of geroscience still lacks: a plausible path from aging biology to an actual lifespan endpoint and then to a commercial product. That makes it one of the more unusual open markets in longevity.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Is organ replacement still open to longevity startups?
Organ replacement remains a huge longevity opportunity, although a new startup will usually have a better chance owning one critical bottleneck than trying to build the entire organ stack.
Xenotransplantation has recently moved much closer to normal clinical development. The FDA cleared United Therapeutics to begin the EXPRESS study of UHeart, a heart derived from pigs carrying ten genetic edits. The trial begins with up to two patients with advanced heart failure and can expand if early safety and efficacy data support further enrollment.
United Therapeutics is already running a separate kidney program. Its infrastructure shows how hard full-stack competition has become. The company operates a designated pathogen-free facility in Virginia with targeted capacity of up to 125 organs per year and is constructing additional facilities in Minnesota and Texas.
Those facilities need controlled animal genetics, pathogen surveillance, manufacturing quality systems, transplant logistics, lifelong infection monitoring and complex immunosuppression. A small startup attempting to reproduce the entire system would need extraordinary capital.
There is much more approachable room around the bottlenecks. Better immune tolerance could reduce chronic immunosuppression. Non-invasive rejection monitoring could detect problems earlier. Organ-preservation systems could increase usable transplant time. Manufacturing tools could improve quality control. Cell-derived tissue and engineered scaffolds could eventually create alternatives to animal organs.
An enabling company can succeed even when somebody else owns the final heart or kidney. Given the amount of capital now required for full-stack xenotransplantation, that may be the better startup position.
Where is there still room in longevity, then?
There is still a lot of room in longevity, but the strongest openings today are muscle preservation, immune rejuvenation, clinically useful aging biomarkers, focused preventive care and the infrastructure needed to turn aging biology into measurable medicine.
We would put muscle near the top. Sarcopenia still has no approved drug, GLP-1 treatment has created a new muscle-preservation problem, and companies such as iBio and Juvena are only beginning to establish what works in people.
Immune rejuvenation looks earlier and riskier, yet the competitive field remains much thinner. TECregen and HexemBio show that serious companies are now forming around thymus and blood-stem-cell aging without anything resembling the capital concentration already seen in reprogramming.
Biomarkers may be the least glamorous opportunity and one of the most important. A fresh analysis across 51 human intervention studies still found substantial disagreement among aging clocks. Until researchers can connect a short-term biomarker change to a meaningful later health outcome, every longevity drug developer faces the same slow clinical problem.
Focused preventive care also remains attractive. Neko and Function have made horizontal testing expensive to attack directly, while Midi shows how a company can start with one urgent stage of life and expand into longer-term prevention after earning the patient relationship.
Dog longevity deserves to stay on the list because the regulatory and experimental setup allows a company to directly test whether treated animals live longer.
We are more selective on senolytics. Human studies justify continued work, especially with better patient selection, but the first commercial generation exposed how easily strong aging biology can disappoint in trials.
Reprogramming has the highest upside and one of the toughest entry points. NewLimit already has hundreds of millions of dollars and Life Biosciences has begun dosing humans. New entrants need a real advantage in delivery, control or tissue selection.
The common thread across the best opportunities is measurable human benefit. Preserving muscle, restoring immunity, improving vision or catching disease earlier gives a startup something patients can feel and clinical trials can test.
That is where we think the market still has the most room.
| Opportunity | Room today | Why we like it | Main thing that could kill it |
|---|---|---|---|
| Muscle and sarcopenia drugs | Very high | No approved sarcopenia drug; GLP-1 use creates fresh demand | Better body composition without better function |
| Longevity biomarkers and trial infrastructure | Very high | Every therapeutic company needs faster human evidence | Biomarkers never become accepted surrogates |
| Immune rejuvenation | High | Huge aging mechanism with few scaled competitors | No convincing clinical endpoint |
| Focused preventive-health platforms | High | Proven demand without requiring new-drug approval | Incumbents expand into every attractive niche |
| Dog longevity | High | Direct lifespan trials are commercially practical | Weak translation and smaller economics than human health |
| Reprogramming delivery and tissue-specific approaches | High but difficult | Fundamental technical problems remain unsolved | Massive capital requirements and safety risk |
| Organ-replacement infrastructure | High but specialized | Clinical xenotransplantation creates many unsolved bottlenecks | Long development cycles and entrenched full-stack players |
| Precision senolytics | Selective | Human results suggest patient selection may matter | Biology continues to disappoint in larger trials |
| Generic biological-age tests | Low | Easy to launch | Scores remain weakly tied to medical decisions |
| Generic longevity testing memberships | Low | Consumer demand is proven | Neko, Function and others already have scale and capital |
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
OUR METHODOLOGY
This analysis asks where there is still room in longevity by separating scientific promise from actual startup opportunity. We looked across therapeutics, preventive health, biomarkers, cellular reprogramming, senolytics, immune rejuvenation, muscle, women's midlife care, companion-animal longevity and organ replacement, then compared where the competitive field is already dense with where the path to proof is becoming clearer.
We gave the most weight to recent evidence that moves closer to measurable benefit: first-in-human trials, FDA or veterinary regulatory milestones, human intervention data, clinical endpoints, commercial adoption and unresolved technical bottlenecks. Funding mattered too, but mainly as a way to judge competitive intensity and capital concentration rather than as proof that a category works.
Human evidence counted more than animal evidence, and disease-specific clinical progress counted more than broad claims about reversing aging. We also treated biomarkers as more useful when they could plausibly connect a short-term biological change with later disease, function or survival.
For preventive health, we compared scale and adoption with the harder question of whether more testing leads to better decisions or outcomes. For therapeutics, we paid particular attention to whether a startup can enter through a recognized disease or loss of function rather than waiting for regulators to treat aging itself as an indication.
Key scientific sources include Nature Medicine's harmonized analysis of epigenetic aging biomarkers across 51 human intervention studies, its review of immune-aging biomarkers for clinical trials, its broader assessment of biological aging clocks, and the randomized Phase 2 senolytic study in postmenopausal women.
Key clinical and regulatory sources include Life Biosciences on the first ER-100 patient dosed, NewLimit on its $435 million financing and path to human trials, Retro Biosciences on RTR242 and its clinical development timeline, iBio on the first participant dosed with IBIO-600, Loyal on LOY-002, the STAY trial and its FDA progress, and United Therapeutics on FDA clearance of the EXPRESS UHeart xenotransplantation trial.
For consumer and preventive-health competition, we used primary company disclosures from Neko Health, Function Health, Prenuvo and Midi Health, alongside the American College of Radiology's position on total-body MRI screening in asymptomatic people.
The final assessment is a synthesis across competitive intensity, clinical maturity, unmet need, regulatory tractability, endpoint quality, capital requirements and remaining technical difficulty. We are more confident where several of those factors point in the same direction, and more cautious where the biology is strong but the path to a useful human endpoint is still weak.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
